1. Management of children with interstitial lung diseases: The difficult issue of acute exacerbations
- Author
-
Clement, A, De Blic, J, Epaud, R, Galeron, L, Nathan, N, Hadchouel, A, Barbato, A, Snijders, D, Kiper, N, Cunningham, S, Griese, M, Bush, A, Schwerk, N, ChILD-EU collaboration, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Physiopathologie des maladies génétiques d'expression pédiatrique, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Intercommunal de Créteil (CHIC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Università degli Studi di Padova = University of Padua (Unipd), Hacettepe University = Hacettepe Üniversitesi, University of Edinburgh, Ludwig-Maximilians University [Munich] (LMU), Dr von Hauner Children's Hospital [Munich, Germany], Ludwig-Maximilians-Universität München (LMU), German Center for Lung Research, Royal Brompton Hospital, Imperial College London, Hannover Medical School [Hannover] (MHH), The project (Orphans Unite, and chILD better together – European Management Platform for Childhood Interstitial Lung Disease) was funded by the FP7-305653-chILD-EU grant. A. Bush is an NIHR SeniorInvestigator, and additionally was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London (London, UK).
- Subjects
MESH: Expert Testimony ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Exacerbation ,Respiratory System ,MEDLINE ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,03 medical and health sciences ,0302 clinical medicine ,MESH: Child ,030225 pediatrics ,Medicine ,Humans ,Respiratory system ,Intensive care medicine ,Child ,Expert Testimony ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,MESH: Humans ,Lung ,business.industry ,Disease progression ,11 Medical And Health Sciences ,respiratory system ,3. Good health ,medicine.anatomical_structure ,030228 respiratory system ,Disease Progression ,MESH: Disease Progression ,business ,Lung Diseases, Interstitial ,MESH: Lung Diseases, Interstitial - Abstract
The study provides the first proposal for acute exacerbation definition in paediatric interstitial lung diseases http://ow.ly/emPs305mpJ6 Interstitial lung disease (ILD) in children (chILD) is an umbrella term for a wide spectrum of rare diseases affecting the lung parenchyma, the causes of which often remain undetermined. These diffuse lung disorders are chronic, and often have high morbidity and mortality [1–3]. The epidemiology of the various forms of chILD is difficult to establish. Extrapolations from small studies have suggested an approximate incidence of 0.5–0.8 cases per 100 000 children [4, 5] However, this is certainly an underestimation due to the lack of standardised definitions, the inadequacy of organised reporting systems, and the variety of pathological conditions. In addition, clinical presentation is often nonspecific, contributing to a poor recognition of these disorders and confusion with other chronic pulmonary diseases. Insufficient disease-specific knowledge creates particular challenges for medical professionals, caregivers and chILD patients. Within the international community of clinicians and researchers involved in paediatric parenchymal lung diseases, the need for multicentre collaborations has resulted in the formation of networks of expertise to improve and harmonise approaches to diagnosis and management of the various forms of chILD. In this context, the present article reports expert opinions on the definition and diagnosis of acute exacerbations, which are major unpredictable deleterious episodes of acute worsening with significant morbidity that punctuate disease course.
- Published
- 2016
- Full Text
- View/download PDF